Stay updated on Cabozantinib for Metastatic Pheochromocytomas Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib for Metastatic Pheochromocytomas Clinical Trial page.

Latest updates to the Cabozantinib for Metastatic Pheochromocytomas Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedEnrollment status on the study page now states 'No longer looking for participants', signaling that participant recruitment is closed. The page also adds new help and navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the site revision tag to v3.6.0, with a minor formatting adjustment to the Intervention/Treatment heading.SummaryDifference0.4%

- Check17 days agoChange DetectedThe site was updated to revision v3.5.5, representing a new build/version of the ClinicalTrials.gov interface; it does not change the study data or displayed content.SummaryDifference0.1%

- Check38 days agoChange DetectedA new revision label, Revision: v3.5.4, was added, replacing Revision: v3.5.3. This reflects a minor update to the page's revision history without altering the study information presented.SummaryDifference0.1%

- Check60 days agoChange DetectedThe page’s displayed system/version footer was updated from “Revision: v3.5.2” to “Revision: v3.5.3.” This represents a platform update rather than a change to the underlying study information.SummaryDifference0.1%

- Check67 days agoChange DetectedThe site version was updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check96 days agoChange DetectedParaganglioma was added to the study conditions and a Genetic and Rare Diseases Information Center resource was included. The page revision was updated from v3.4.3 to v3.5.0.SummaryDifference0.2%

Stay in the know with updates to Cabozantinib for Metastatic Pheochromocytomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib for Metastatic Pheochromocytomas Clinical Trial page.